Moderna Inc. ($MRNA) Stock Forecast: Up 6.1% Today

What is Moderna Inc.?

Moderna (MRNA) is a biotechnology company recognized for its innovative mRNA technology in vaccine development, leading to a favorable market sentiment towards the company.

Why is Moderna Inc. going up?

MRNA stock is up 6.1% on Jan 16, 2026 20:55

• Moderna's optimistic outlook today is linked to its increased full-year 2025 revenue guidance to $1.9 billion, demonstrating significant growth potential.
• The positive trajectory is supported by Moderna's cost-cutting initiatives, an enhanced cash balance projection, and the ongoing phase three melanoma trial identified as a key driver for 2026 by RBC Capital.
• The decline in Arbutus Biopharma's stock value, stemming from a patent dispute with Moderna, may have inadvertently influenced Moderna's upward trend as investors may view Moderna as solidifying its competitive standing in the biopharmaceutical sector.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

I Hope Moderna (MRNA) Posts Growth, Says Jim Cramer

Jim Cramer expressed hope for Moderna's continued growth, despite past disappointments, following the company's optimistic full-year 2025 revenue guidance increase to $1.9 billion. Moderna also cut operating expenses and increased its cash balance estimate. Analysts from Jefferies and RBC Capital maintained neutral ratings, with RBC highlighting Moderna's phase three melanoma trial as a key 2026 catalyst.

https://finviz.com/news/279145/i-hope-moderna-mrna-posts-growth-says-jim-cramer

Quanta Services stock hits all-time high at 474.14 USD

Quanta Services (PWR) stock has reached an all-time high of $474.14, marking a 40.1% increase over the past year and reflecting strong investor confidence. The company also announced a 10% increase in its quarterly dividend to $0.11 per share. Several financial firms, including JPMorgan and Seaport Global Securities, have upgraded their ratings and raised price targets for Quanta Services, anticipating continued growth from large projects and its strong position in the U.S. power sector.

https://www.investing.com/news/company-news/quanta-services-stock-hits-alltime-high-at-47414-usd-93CH-4452272

VSE Corporation stock hits all-time high at 215.35 USD

VSE Corporation's stock reached an all-time high of $215.35, reflecting significant growth with a 108.42% 1-year price return and a 64.04% gain in the last six months. This performance, along with 49 consecutive years of dividend payments and recent acquisition of Aero 3, demonstrates strong investor confidence. The company's Q3 2025 earnings also surpassed expectations, further solidifying its market position.

https://www.investing.com/news/company-news/vse-corporation-stock-hits-alltime-high-at-21535-usd-93CH-4452250

Arbutus falls as patent row with Moderna hits EU snag (ABUS)

Arbutus Biopharma (ABUS) shares fell significantly after the European Patent Office revoked one of its patents involved in a dispute with Moderna (MRNA). The patent revocation is a setback for Arbutus in its ongoing legal battles surrounding intellectual property.

https://seekingalpha.com/news/4539792-arbutus-falls-patent-row-moderna-hits-eu-snag

European Patent Office revokes Arbutus Biopharma patent following appeal

The European Patent Office's Board of Appeal has revoked Arbutus Biopharma Corporation's European patent EP 2279254, a decision the company disagrees with and plans to challenge. Despite this, Arbutus does not anticipate the revocation to impact its ongoing patent infringement cases against Moderna, Pfizer, and BioNTech in other jurisdictions like the U.S., Japan, and Canada, citing that the ruling was based on "added matter" which is not applicable there. The company maintains a strong liquidity position, as indicated by InvestingPro data, and has recently reported encouraging clinical data for its hepatitis B treatment despite a third-quarter loss.

https://www.investing.com/news/sec-filings/european-patent-office-revokes-arbutus-biopharma-patent-following-appeal-93CH-4451880

Trending Today

Moderna Inc. ($MRNA) Stock Forecast: Up 6.1% Today

Digital Turbine, Inc. ($APPS) Stock Forecast: Down 5.8% Today

Voya Financial Inc. ($VOYA) Stock Forecast: Down 4.9% Today

Mobileye Global ($MBLY) Stock Forecast: Down 5.1% Today

Cassava Sciences, Inc. ($SAVA) Stock Forecast: Down 5.2% Today

State Street Corporation ($STT) Stock Forecast: Down 5.1% Today

TripAdvisor Inc. ($TRIP) Stock Forecast: Down 5.1% Today

Micron Technology Inc. ($MU) Stock Forecast: Up 5.0% Today

Draftkings Inc ($DKNG) Stock Forecast: Down 7.7% Today

Super Micro Computer Inc ($SMCI) Stock Forecast: Up 8.2% Today

Moderna Inc. Price History

13.00.2026 - MRNA Stock was up 17.4%

• Moderna's stock saw a notable 12% increase following the release of its optimistic 2025 financial forecasts, reflecting strong investor trust in the company's potential for future growth.
• The company's strategic pivot towards infectious diseases, oncology, and rare diseases, combined with operational cost reductions and advancements in its pipeline, have reinforced Moderna's long-term prospects and supported the positive market response.
• Encouraging announcements made at the J.P. Morgan Healthcare Conference, such as anticipated revenue growth in 2026 and progress in late-stage pipeline developments, have further bolstered investor confidence and contributed to the stock's upward trajectory.
• Moderna's recent market success stems from a blend of promising financial forecasts, strategic focus on key therapeutic areas, and favorable updates on its pipeline and business outlook.

13.00.2026 - MRNA Stock was up 16.6%

• Following various favorable developments, Moderna's stock witnessed a significant bullish surge:
• The unveiling of its 2025 financial forecasts displaying promising growth potential led to a 12% increase in stock value.
• Optimistic news regarding its business and pipeline at the J.P. Morgan Healthcare Conference heightened investor confidence.
• Analyst upgrades and company initiatives strengthened investor belief in Moderna's future performance.
• Technical analysis indicates a potential upward trend for Moderna's stock, suggesting a breakout after a period of underwhelming performance.
• Moderna's strategic pivot towards infectious disease, oncology, and rare diseases, coupled with key catalysts like Intismeran/Keytruda Phase II and III readouts, has attracted long-term investors despite near-term revenue setbacks, presenting a high-risk recovery narrative.
• Overall, a series of positive developments, robust financial projections, and strategic moves have driven Moderna's stock price up, signaling an optimistic outlook for the company in the near term.

16.00.2026 - MRNA Stock was up 6.6%

• Moderna witnessed a significant surge in its stock performance recently.
• The notable uptick in the market's reaction is linked to Moderna's optimistic preliminary sales projection for 2025 and favorable business prospects for 2026 onwards. These projections involve updated forecasts for operating expenses, improved cash reserves, and anticipated milestones in its product pipeline, such as upcoming regulatory submissions for novel vaccines and advancements in personalized cancer treatments.
• Despite the projected decrease in revenue due to declining demand for COVID vaccines, Moderna's strategic announcements have bolstered investor confidence in its future growth trajectory.
• The recent invalidation of a patent owned by Arbutus Biopharma, a company engaged in legal disputes with Moderna, could have positively influenced Moderna's stock price by potentially resolving some legal uncertainties for Moderna in the European market.

08.00.2026 - MRNA Stock was down 5.3%

• Moderna experienced a bearish trend today, possibly due to investors taking profits following a recent surge in the stock price.
• The positive updates on Moderna's enhanced COVID-19 vaccine combating the LP.8.1 variant may have been factored into the stock price, prompting a sell-off after the announcement.
• Investor caution could be influenced by potential competition and legal issues affecting other biotech firms like BioNTech, which could impact Moderna's market standing and revenue in the future.
• While Moderna continues to make significant progress in vaccine development, short-term stock movements can be influenced by market dynamics and external factors.

16.00.2026 - MRNA Stock was up 6.1%

• Moderna's optimistic outlook today is linked to its increased full-year 2025 revenue guidance to $1.9 billion, demonstrating significant growth potential.
• The positive trajectory is supported by Moderna's cost-cutting initiatives, an enhanced cash balance projection, and the ongoing phase three melanoma trial identified as a key driver for 2026 by RBC Capital.
• The decline in Arbutus Biopharma's stock value, stemming from a patent dispute with Moderna, may have inadvertently influenced Moderna's upward trend as investors may view Moderna as solidifying its competitive standing in the biopharmaceutical sector.

15.00.2026 - MRNA Stock was down 5.0%

• Moderna's stocks saw a downward trend today, potentially as investors took profits after a 17% jump post the positive initial financial results for 2025.
• There are concerns among analysts and investors regarding Moderna's shift away from solely focusing on COVID-19 vaccines to a more extensive pharmaceutical range, particularly in light of upcoming critical events like the Phase 3 cancer vaccine trial outcome and patent dispute.
• The recent downgrade of Absci Corporation (ABSI) by a financial institution could have impacted the market sentiment surrounding biotech firms like Moderna, underscoring the sector's inherent risks.
• Despite the recent decline in stock value, Moderna's strategic evolution and ongoing progress in its pipeline projects suggest that it could maintain a significant position in the pharmaceutical landscape over the long haul.

14.00.2026 - MRNA Stock was up 13.7%

• Moderna's stock saw a significant increase today due to an optimistic revenue outlook for 2026, anticipating up to $1.9 billion in revenue and potential vaccine approvals.
• Moderna's positive performance contrasts with the challenges faced by Apellis Pharmaceuticals, whose stock prices have declined despite positive revenue updates, reflecting market sentiment discrepancies.
• The recent acquisition offer by BioNTech for CureVac has brought stability to CureVac's stock, underscoring the significance of strategic partnerships in the biotech field.
• The upbeat movement in Moderna's stock might also be influenced by the growing focus on vaccine manufacturers like Novavax, as the CDC notes a surge in respiratory ailments, creating a favorable landscape for vaccine-related companies.

14.00.2026 - MRNA Stock was up 6.2%

• Moderna's stock saw a significant 17% increase after announcing strong preliminary financial results for full-year 2025, surpassing revenue expectations and predicting growth for 2026.
• Investor confidence in Moderna's future prospects grew as the market reacted positively to the company's shift towards a multi-product respiratory franchise and personalized cancer treatments.
• The bullish trend was influenced by expectations surrounding upcoming events like the Phase 3 cancer vaccine trial results and a patent trial in late 2026, with potential implications for Moderna's market position and valuation.
• Moderna's strategies to lower operating costs, achieve cash flow breakeven by 2028, and advance its pipeline, notably in seasonal vaccines, oncology, and rare diseases, further bolstered investor optimism and drove up the stock price.

06.00.2026 - MRNA Stock was up 6.0%

• Moderna's stock observed a positive uptrend today due to encouraging updates on the company's vaccine progress and submissions for its seasonal influenza vaccine candidates.
• The recent funding from CEPI for a crucial Phase 3 trial on Moderna's mRNA-based H5 pandemic influenza vaccine reflects a strong vote of confidence in the company's technology and its potential role in global pandemic readiness.
• Regulatory filings for Moderna's mRNA-1010 seasonal influenza vaccine in significant markets like the U.S., EU, Canada, and Australia, supported by favorable Phase 3 trial results, have boosted investor confidence in the company's future growth prospects.
• Moderna's confirmed revenue outlook and forthcoming milestones, including the launch of multiple vaccines post-COVID-19, signal a solid long-term strategy that has resonated well with investors, underpinning the optimistic market sentiment towards the stock.

06.00.2026 - MRNA Stock was up 11.9%

• The rise in Moderna's stock today is linked to encouraging developments related to the company's vaccine technology:
• Funding from CEPI for a pivotal Phase 3 trial on Moderna's mRNA-based H5 pandemic influenza vaccine candidate indicates strong belief in the company's technology and its potential for global pandemic preparedness.
• Regulatory submissions for Moderna's seasonal influenza vaccine, mRNA-1010, in various countries, backed by favorable Phase 3 study results, underscore the company's dedication to broadening its vaccine range and addressing public health requirements.
• Moderna's focus on using mRNA technology to better align with changing flu strains and its dedication to keeping vaccine prices reasonable and ensuring equal access for lowto middle-income nations further increases investor confidence in the company's growth prospects.
• Positive clinical trial outcomes, advancements in regulatory processes, and strategic moves in vaccine creation collectively position Moderna as a significant player in the healthcare industry, boosting investor confidence and contributing to today's bullish market activity.

06.00.2026 - MRNA Stock was up 11.5%

• Moderna's stock price saw a significant upsurge today following the company's submission of regulatory filings for its seasonal influenza vaccine, mRNA-1010, in multiple countries. This announcement has sparked investor confidence in the expansion of Moderna's non-COVID product range and the growth potential of its flu vaccine.
• The rise in Moderna's stock price was also supported by BofA Global Research raising its price target for the company, indicating strong belief in its new product releases and future opportunities.
• Despite analysts maintaining a "Reduce" consensus rating on Moderna due to concerns about revenue decline and profitability, the positive updates on the flu vaccine submissions and cost-saving measures have overshadowed these reservations, propelling the stock's bullish performance today.
• A global market analysis forecast predicting substantial growth in the mRNA cancer vaccine biologic lines market has likely bolstered the optimistic sentiment surrounding Moderna, underlining its potential for further expansion and revenue generation in the biotech industry.

13.00.2026 - MRNA Stock was up 7.7%

• Moderna's positive momentum today is linked to updates shared at the 44th Annual J.P. Morgan Healthcare Conference. Notably, the company revealed optimistic revenue growth forecasts for 2026 and progress in advancing its late-stage pipeline.
• Investor confidence in Moderna was likely bolstered by expectations of potential product approvals for flu and flu/COVID combinations in 2026, alongside upcoming pivotal trial data releases in various therapeutic areas.
• The appointment of Moderna's CEO, Stephane Bancel, to the Board of Directors of Commonwealth Fusion Systems is seen as a positive move that highlights Bancel's expertise and the potential synergies between the two companies.
• The company's strategic focus on key therapeutic areas, coupled with the encouraging outlook presented at the conference, has generated optimism among investors and propelled Moderna's stock performance.